A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients

Transplantation

Volumn 63, Issue 10, 1997, Pages 1435-1440

  Chan, Christopher ^b   Maurer, Janet ^a   Cardella, Carl ^b   Cattran, Dan ^b   Pei, York ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b 13 EN 228 ^*

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; ATENOLOL; AZATHIOPRINE; CIMETIDINE; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN A; INULIN; PLACEBO; PREDNISONE; VERAPAMIL;

4 AMINOHIPPURIC ACID CLEARANCE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; INULIN CLEARANCE; KIDNEY PLASMA FLOW; LUNG TRANSPLANTATION; MALE; MEAN ARTERIAL PRESSURE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; COSTS AND COST ANALYSIS; CYCLOSPORINE; FEMALE; GLOMERULAR FILTRATION RATE; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; MALE; MIDDLE AGED; VERAPAMIL;

EID: 0030914820     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199705270-00012     Document Type: Article

References (26)

1. Cohen D, Loertscher R, Rubin M, et al. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med 1984; 101: 667.
2. Hannedouche T, Delgado A, Gnionsahe A, et al. Nephrotoxicity of cyclosporine in auto-immune diseases. Adv Nephrol 1990; 19: 169.
3. Palestine A, Austin H, Balow J, et al. Renal pathologic alterations in patients treated with cyclosporine A for uveitis. N Engl J Med 1986; 314: 1293.
4. Myers B, Newton L, Boshkos C, et al. Chronic injury of human renal microvessels with low-dose cyclosporine. Transplantation 1988; 46: 694.
5. Myers B, Subley R, Newton L, et al. Long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590.
6. Nizze H, Mihatsch M, Zollinger H, et al. Cyclosporine-associated nephropathy in patients with heart and bone marrow transplants. Clin Nephrol 1988; 30: 248.
7. Pei Y, Chan C, Cattran D, et al. Sustained vasoconstriction associated with daily cyclosporine dose in heart and lung transplant recipients: potential pathophysiologic role of endothelin. J Lab Clin Med 1995; 125: 113.
8. Ramies G, Bertani T. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989; 13: 261.
9. Mihatsch M, Thiel G, Ryffel B. Cyclosporine nephrotoxicity. Adv Nephrol 1988; 17: 303.
10. Kirk A, Omar I, Bateman D, Dark J. Cyclosporine-associated hypertension in cardiopulmonary transplantation: the beneficial effect of nifedipine on renal function. Transplantation 1989; 48: 428.
11. Piero R, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706.
12. Dawidson I, Rooth P, Fry W, et al. Prevention of acute cyclosporine-induced renal blood flow inhibition and improved immunosuppression with verapamil. Transplantation 1989; 50: 575.
13. Kirk A, Omar I, Dark J. Long-term improvement in renal function using nifedipine in cyclosporine-associated hypertension. Transplantation 1990; 50: 1061.
14. Bunke M, Ganzel B. Effect of calcium channel antagonists on renal function in hypertensive heart transplant recipients. J Heart Lung Transplant 1992; 11: 1194.
15. Fjeldbo W, Stamey TA. Adapted method for determination of inulin in serum and urine with autoanalyser. J Lab Clin Med 1968; 72: 353.
16. Smith HW, Finkelstein N, Aliminosa L, Crawford B, Graber M. The renal clearances of substituted hippuric acid and derivatives and other aromatic acids in dog and man. J Clin Invest 1945; 24: 338.
17. Liedtke R, Duarte C. Laboratory protocols and methods for the measurement of glomerular filtration rate and renal plasma flow. In: Duarte C, ed. Renal function test, 1st ed. Boston: C. Little Brown, 1980: 49.
18. Kopp J, Klotman P. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1990; 1: 162.
19. Kohan DE. Endothelins in the kidney: physiology and pathophysiology. Am J Kidney Dis 1993; 22: 493.
20. Perico N, Ruggenenti P, Gaspari F, et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992; 54: 56.
21. English J, Evan A, Houton D, Bennett W. Cyclosporine-induced acute renal dysfunction in the rat: evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44: 135.
22. Carmines P, Navar L. Disparate effects of Ca channel blockade on afferent and efferent arteriolar response to ANG II. Am J Physiol 1989; 256: F1015.
23. Palmer B, Dawidson I, Sagalowsky A, Sandor Z, Lu C. Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 1991; 52: 640.
24. Pirsch J, D'Alessandro A, Roecker E, et al. A controlled, double-blind, randomized trial of verapamil and cyclosporine in cadaver renal transplant patients. Am J Kidney Dis 1993; 21: 189.
25. Wadhwa N, Scroeder T, Pesce A, et al. Cyclosporine drug interactions: a review. Ther Drug Monitor 1987; 9: 399.
26. Renton K. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol 1985; 34: 549.